APAC Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 CELL SOURCE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET APPLICATION COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 52
5 ASIA PACIFIC MEDICAL CARTS MARKET: REGULATIONS 54
5.1 REGULATION IN U.S. 54
5.2 REGULATION IN CANADA 55
5.3 REGULATION IN EUROPE 55
5.4 REGULATION IN INDIA 55
5.5 REGUALTION IN JAPAN 56

6 MARKET OVERVIEW 58
6.1 DRIVERS 60
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS 60
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS 60
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES 61
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY 63
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT 64
6.2 RESTRAINT 65
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS 65
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 65
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS 66
6.3 OPPORTUNITIES 66
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS 66
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE 67
6.3.3 SURGE IN HEALTHCARE EXPENDITURE 67
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 68
6.4 CHALLENGES 69
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE 69
6.4.2 LACK OF SKILLED PROFESSIONALS 69
6.4.3 STRINGENT REGULATORY FRAMEWORK 69
7 IMPACT OF COVID-19 ON THE ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 71
7.1 IMPACT ON PRICE 71
7.2 IMPACT ON DEMAND 71
7.3 IMPACT ON SUPPLY CHAIN 72
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 72
7.5 CONCLUSION 73
8 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 74
8.1 OVERVIEW 75
8.2 SKIN CELLS 77
8.2.1 FIBROBLAST 78
8.2.2 KERATINOCYTES 78
8.2.3 ADIPOSE DERIVED STEM CELLS 79
8.2.4 HEPATOCYTES 79
8.2.5 MELANOCYTES 79
8.2.6 NEURAL STEM CELLS 79
8.2.7 OTHERS 79
8.3 BLOOD CELLS 79
8.3.1 PERIPHERAL BLOOD 80
8.3.2 CORD BLOOD ENDOTHELIAL CELLS 80
8.3.3 CORD BLOOD STEM CELLS 80
8.3.4 OTHERS 80
9 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE 81
9.1 OVERVIEW 82
9.2 HUMAN IPSCS 85
9.3 MOUSE IPSCS 85
10 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT 87
10.1 OVERVIEW 88
10.2 CONSUMABLES & KITS 91
10.2.1 REPROGRAMMING KITS 92
10.2.2 MEDIA 92
10.2.3 TRANSFECTION KITS 92
10.2.4 CELL IDENTIFICATION KITS 92
10.2.5 ACCESSORIES 92
10.2.6 OTHERS 92
10.3 SERVICES 92
10.4 INSTRUMENTS 93
10.4.1 IMAGING SYSTEMS 94
10.4.2 ELECTROPORATION DEVICE 94
10.4.3 INCUBATORS 94
10.4.4 OTHERS 94
11 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 95
11.1 OVERVIEW 96
11.2 DRUG DISCOVERY AND DEVELOPMENT 99
11.3 ACADEMIC RESEARCH 99
11.4 DISEASE MODELLING 100
11.5 CELLULAR THERAPY 101
11.6 REGENERATIVE MEDICINE 101
11.7 TOXICOLOGY SCREENING 102
11.8 STEM CELL BANKING 103
11.9 3D BIOPRINTING 103
11.10 OTHERS 104
12 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER 105
12.1 OVERVIEW 106
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 109
12.3 RESEARCH LABORATORIES 109
12.4 DIAGNOSTIC LABORATORIES 110
12.5 OTHERS 111
13 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 112
13.1 OVERVIEW 113
13.2 DIRECT TENDER 115
13.3 RETAIL SALES 116
14 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION 117
14.1 ASIA-PACIFIC 118
14.1.1 CHINA 127
14.1.2 JAPAN 130
14.1.3 INDIA 133
14.1.4 SOUTH KOREA 136
14.1.5 AUSTRALIA 139
14.1.6 SINGAPORE 142
14.1.7 THAILAND 145
14.1.8 MALAYSIA 148
14.1.9 INDONESIA 151
14.1.10 PHILIPPINES 154
14.1.11 REST OF ASIA-PACIFIC 157
15 ASIA PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 158
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 158
16 SWOT ANALYSIS 159

17 COMPANY PROFILE 160
17.1 FUJIFILM CORPORATION 160
17.1.1 COMPANY SNAPSHOT 160
17.1.2 REVENUE ANALYSIS 160
17.1.3 COMPANY SHARE ANALYSIS 161
17.1.4 PRODUCT PORTFOLIO 161
17.1.5 RECENT DEVELOPMENT 162
17.1.5.1 ACQUISITION 162
17.2 THERMO FISHER SCIENTIFIC INC. 163
17.2.1 COMPANY SNAPSHOT 163
17.2.2 REVENUE ANALYSIS 163
17.2.3 COMPANY SHARE ANALYSIS 164
17.2.4 PRODUCT PORTFOLIO 164
17.2.5 RECENT DEVELOPMENTS 167
17.2.5.1 EVENT 167
17.2.5.2 ACQUISITION 168
17.3 LONZA. 169
17.3.1 COMPANY SNAPSHOT 169
17.3.2 REVENUE ANALYSIS 169
17.3.3 COMPANY SHARE ANALYSIS 170
17.3.4 PRODUCT PORTFOLIO 170
17.3.5 RECENT DEVELOPMENTS 171
17.3.5.1 EXPANSION 171
17.4 MERCK KGAA 172
17.4.1 COMPANY SNAPSHOT 172
17.4.2 REVENUE ANALYSIS 172
17.4.3 COMPANY SHARE ANALYSIS 173
17.4.4 PRODUCT PORTFOLIO 173
17.4.5 RECENT DEVELOPMENT 176
17.4.5.1 AGREEMENT 176
17.5 EVOTEC SE. 177
17.5.1 COMPANY SNAPSHOT 177
17.5.2 REVENUE ANALYSIS 177
17.5.3 COMPANY SHARE ANALYSIS 178
17.5.4 PRODUCT PORTFOLIO 178
17.5.5 RECENT DEVELOPMENTS 178
17.5.5.1 AGREEMENT 178
17.5.5.2 COLLABORATION 179

17.6 APPLIED STEMCELL. 180
17.6.1 COMPANY SNAPSHOT 180
17.6.2 PRODUCT PORTFOLIO 180
17.6.3 RECENT DEVELOPMENTS 186
17.6.3.1 PRODUCT LAUNCH 186
17.7 AXOL BIOSCIENCE LTD. 187
17.7.1 COMPANY SNAPSHOT 187
17.7.2 PRODUCT PORTFOLIO 187
17.7.3 RECENT DEVELOPMENTS 190
17.7.3.1 MERGER 190
17.7.3.2 PRODUCT LAUNCH 191
17.8 CELL APPLICATIONS, INC. 192
17.8.1 COMPANY SNAPSHOT 192
17.8.2 PRODUCT PORTFOLIO 192
17.8.3 RECENT DEVELOPMENT 193
17.8.3.1 PARTNERSHIP 193
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 194
17.9.1 COMPANY SNAPSHOT 194
17.9.2 REVENUE ANALYSIS 194
17.9.3 PRODUCT PORTFOLIO 195
17.9.4 RECENT DEVELOPMENT 195
17.9.4.1 ACQUISITION 195
17.10 CITIUS PHARMACEUTICALS, INC. 196
17.10.1 COMPANY SNAPSHOT 196
17.10.2 PRODUCT PORTFOLIO 196
17.10.3 RECENT DEVELOPMENT 196
17.10.3.1 AGREEMENT 196
17.11 CORNING INCORPORATED 197
17.11.1 COMPANY SNAPSHOT 197
17.11.2 REVENUE ANALYSIS 197
17.11.3 PRODUCT PORTFOLIO 198
17.11.4 RECENT DEVELOPMENT 198
17.11.4.1 AGREEMENT 198
17.12 FATE THERAPEUTICS 199
17.12.1 COMPANY SNAPSHOT 199
17.12.2 PRODUCT PORTFOLIO 199
17.12.3 RECENT DEVELOPMENT 199
17.12.3.1 CLINICAL TRIAL 199

17.13 GENECOPOEIA, INC. 200
17.13.1 COMPANY SNAPSHOT 200
17.13.2 PRODUCT PORTFOLIO 200
17.13.3 RECENT DEVELOPMENT 200
17.14 HOPSTEM BIOTECHNOLOGY LLC. 201
17.14.1 COMPANY SNAPSHOT 201
17.14.2 PRODUCT PORTFOLIO 201
17.14.3 RECENT DEVELOPMENT 201
17.14.3.1 PARTNERSHIP 201
17.15 HORIZON DISCOVERY LTD. 202
17.15.1 COMPANY SNAPSHOT 202
17.15.2 PRODUCT PORTFOLIO 202
17.15.3 RECENT DEVELOPMENT 202
17.16 LUMACYTE 203
17.16.1 COMPANY SNAPSHOT 203
17.16.2 PRODUCT PORTFOLIO 203
17.16.3 RECENT DEVELOPMENT 204
17.16.3.1 COLLABORATION 204
17.17 R & D SYSTEMS, INC. 205
17.17.1 COMPANY SNAPSHOT 205
17.17.2 REVENUE ANALYSIS 205
17.17.3 PRODUCT PORTFOLIO 206
17.17.4 RECENT DEVELOPMENT 207
17.18 REPROCELL INC. 208
17.18.1 COMPANY SNAPSHOT 208
17.18.2 PRODUCT PORTFOLIO 208
17.18.3 RECENT DEVELOPMENTS 209
17.18.3.1 COLLABORATION 209
17.18.3.2 FACILITY EXPANSION 210
17.18.3.3 SERVICE LAUNCH 210
17.19 TAKARA BIO INC. 211
17.19.1 COMPANY SNAPSHOT 211
17.19.2 REVENUE ANALYSIS 211
17.19.3 PRODUCT PORTFOLIO 212
17.19.4 RECENT DEVELOPMENTS 212
17.19.4.1 NEW FACILITY LAUNCH 212

17.20 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY) 213
17.20.1 COMPANY SNAPSHOT 213
17.20.2 REVENUE ANALYSIS 213
17.20.3 PRODUCT PORTFOLIO 214
17.20.4 RECENT DEVELOPMENT 214
17.20.4.1 ACQUISITION 214
18 QUESTIONNAIRE 215
19 RELATED REPORTS 219